HK1049998B - 具有抗腫瘤和抗血管生成活性的半合成紫杉烷 - Google Patents

具有抗腫瘤和抗血管生成活性的半合成紫杉烷

Info

Publication number
HK1049998B
HK1049998B HK03102021.6A HK03102021A HK1049998B HK 1049998 B HK1049998 B HK 1049998B HK 03102021 A HK03102021 A HK 03102021A HK 1049998 B HK1049998 B HK 1049998B
Authority
HK
Hong Kong
Prior art keywords
del
ins
sup
delete
date
Prior art date
Application number
HK03102021.6A
Other languages
English (en)
Other versions
HK1049998A1 (en
Inventor
Bombardelli Ezio
Pontiroli Alessandro
Original Assignee
Indena Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena Spa filed Critical Indena Spa
Publication of HK1049998A1 publication Critical patent/HK1049998A1/xx
Publication of HK1049998B publication Critical patent/HK1049998B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK03102021.6A 2000-01-18 2003-03-19 具有抗腫瘤和抗血管生成活性的半合成紫杉烷 HK1049998B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000MI000056A IT1317731B1 (it) 2000-01-18 2000-01-18 Tassani semisintetici con attivita' antitumorale ed antiangiogenetica.
PCT/EP2001/000386 WO2001053282A1 (en) 2000-01-18 2001-01-15 Semi-synthetic taxanes with antitumor and antiangiogenetic activities

Publications (2)

Publication Number Publication Date
HK1049998A1 HK1049998A1 (en) 2003-06-06
HK1049998B true HK1049998B (zh) 2005-04-01

Family

ID=11443708

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03102021.6A HK1049998B (zh) 2000-01-18 2003-03-19 具有抗腫瘤和抗血管生成活性的半合成紫杉烷

Country Status (24)

Country Link
US (2) US6589979B2 (zh)
EP (1) EP1248776B1 (zh)
JP (1) JP4986354B2 (zh)
KR (1) KR100813704B1 (zh)
CN (1) CN1176916C (zh)
AT (1) ATE271044T1 (zh)
AU (1) AU781650B2 (zh)
CA (1) CA2397591C (zh)
CZ (1) CZ301251B6 (zh)
DE (1) DE60104281T2 (zh)
DK (1) DK1248776T3 (zh)
ES (1) ES2223778T3 (zh)
HK (1) HK1049998B (zh)
HU (1) HU229347B1 (zh)
IL (1) IL150787A0 (zh)
IT (1) IT1317731B1 (zh)
NO (1) NO329403B1 (zh)
PL (1) PL202591B1 (zh)
PT (1) PT1248776E (zh)
RU (1) RU2259363C2 (zh)
SI (1) SI1248776T1 (zh)
SK (1) SK285683B6 (zh)
TR (1) TR200401811T4 (zh)
WO (1) WO2001053282A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1688415A1 (en) * 2004-12-07 2006-08-09 Aventis Pharma S.A. Cytotoxic agents comprising new C-2 modified taxanes
ITMI20050415A1 (it) * 2005-03-15 2006-09-16 Indena Spa Derivati tassanici semi-sintetici ad attivita' antitumorale
CN105849086B (zh) 2012-11-24 2018-07-31 杭州多禧生物科技有限公司 亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
AU2015242213A1 (en) 2015-07-12 2018-03-08 Hangzhou Dac Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
US20210308277A1 (en) 2016-11-14 2021-10-07 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175315A (en) * 1989-05-31 1992-12-29 Florida State University Method for preparation of taxol using β-lactam
CA2109861C (en) * 1992-12-04 1999-03-16 Shu-Hui Chen 6,7-modified paclitaxels
CA2195844C (en) * 1994-07-26 2001-10-09 Ezio Bombardelli Semi-synthetic taxanes with anti-tumoural activity

Also Published As

Publication number Publication date
AU3369401A (en) 2001-07-31
HU229347B1 (hu) 2013-11-28
EP1248776B1 (en) 2004-07-14
WO2001053282A1 (en) 2001-07-26
KR20020068082A (ko) 2002-08-24
JP2003520792A (ja) 2003-07-08
HUP0204344A3 (en) 2004-01-28
US20030028038A1 (en) 2003-02-06
TR200401811T4 (tr) 2004-09-21
DE60104281T2 (de) 2005-08-18
USRE39723E1 (en) 2007-07-10
SK285683B6 (sk) 2007-06-07
US6589979B2 (en) 2003-07-08
CA2397591C (en) 2009-10-20
IL150787A0 (en) 2003-02-12
PT1248776E (pt) 2004-10-29
HUP0204344A2 (en) 2003-05-28
CZ301251B6 (cs) 2009-12-23
RU2002119060A (ru) 2004-01-10
RU2259363C2 (ru) 2005-08-27
NO20023428L (no) 2002-09-16
ATE271044T1 (de) 2004-07-15
SK10562002A3 (sk) 2002-11-06
NO20023428D0 (no) 2002-07-17
NO329403B1 (no) 2010-10-11
ITMI20000056A1 (it) 2001-07-18
CZ20022478A3 (cs) 2002-10-16
IT1317731B1 (it) 2003-07-15
PL202591B1 (pl) 2009-07-31
JP4986354B2 (ja) 2012-07-25
ITMI20000056A0 (it) 2000-01-18
DE60104281D1 (de) 2004-08-19
DK1248776T3 (da) 2004-11-22
KR100813704B1 (ko) 2008-03-13
PL356272A1 (en) 2004-06-28
CN1395571A (zh) 2003-02-05
HK1049998A1 (en) 2003-06-06
EP1248776A1 (en) 2002-10-16
CA2397591A1 (en) 2001-07-26
AU781650B2 (en) 2005-06-02
ES2223778T3 (es) 2005-03-01
SI1248776T1 (en) 2004-10-31
CN1176916C (zh) 2004-11-24

Similar Documents

Publication Publication Date Title
TR200200717T2 (tr) Terapötik kinazolin türevleri.
EP1154782A4 (en) TAXAN DERIVATIVES FOR TARGETED CANCER THERAPY
EA200000282A1 (ru) Способ введения таксана пациенту, нуждающемуся в лечении таксаном, способ лечения человека таксаном (варианты)
HK1097189A1 (en) Cannabinoid receptor ligands
DE69728152D1 (en) Hoch-lipophile campothecin-derivate
GB2334521A (en) Anthranilic acid derivatives as multi drug resistance modulators
BR0010746A (pt) Derivados heterocìclicos úteis com agentes anticâncer
PL364811A1 (en) Indolyl-3-glyoxylic acid derivatives serving as antitumor agents
EP1017675A4 (en) HIGHLY LIPOPHILIC CAMPTOTHECIN DERIVATIVES
PT1212312E (pt) Novos derivados de flavonas xantonas e cumarinas
ATE238981T1 (de) Antitumorwirkstoffe
BG104436A (en) The administration of macrolides for the treatment of cancer and macular degeneration
ATE268174T1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
HK1049998A1 (en) Semi-synthetic taxanes with antitumor and antiangiogenetic activities.
NO20031410D0 (no) Antitumorterapi innbefattende distamycinderivater
EE200200681A (et) Akrüloüüldistamütsiini derivaati sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritudravimpreparaat
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
NZ337048A (en) Use of N-[1-methyl-(substituted phenyl)ethyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide derivatives to treat prostate cancer
Su et al. Antitumor therapeutic effects of new gene-targeted alkylating agents, 9-anilinoacridines bearing an alkylating N-mustard residue on the acridine chromophore

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200115